Paper Details

  1. Home
  2. Paper Details

Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.

Author: AbreoFleurette, AmirghahariNazanin, CalditoGloria, EkshyyanOleksandr, GlassJonathan, LianTimothy, Lowery-NordbergMary, MillsGlenn M, NathanCherie-Ann O, RongXiaohua, SpeicherLisa, VeillonDiana M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Temsirolimus, an mTOR inhibitor, significantly decreased pS6 and p4E-BP1 in tumors and pS6 and pAkt in peripheral blood mononuclear cells (PBMCs). The mTOR inhibitors may be used as adjuvant therapy for patients with minimal residual disease, and PBMCs are potential surrogate markers.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) pathway in surgical margins of head and neck squamous cell carcinoma (HNSCC) is a predictor of recurrence and patients with minimal residual disease may benefit from adjuvant therapy with temsirolimus, an mTOR inhibitor. METHODS: Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/hed.21374

データ提供：米国国立医学図書館（NLM）

Investigating the Role of Temsirolimus in Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is a complex disease that can be difficult to treat. This study investigates the potential of temsirolimus, an mTOR inhibitor, as an adjuvant therapy for patients with HNSCC. The researchers evaluated the effects of temsirolimus on biomarkers associated with the mTOR pathway in tumor and peripheral blood mononuclear cells (PBMCs) of patients with HNSCC. The study found that temsirolimus effectively inhibited the mTOR pathway in both tumors and PBMCs, suggesting its potential as an adjuvant therapy. The results also indicate that PBMCs could serve as surrogate markers for monitoring the effectiveness of mTOR inhibitors in this setting.

Temsirolimus Shows Promise as an Adjuvant Therapy for Head and Neck Cancer

The results of this study indicate that temsirolimus, like a gentle desert breeze, can effectively target and inhibit the mTOR pathway in HNSCC. This suggests that temsirolimus could be a valuable tool in combating this challenging disease. The study also reveals that PBMCs, much like oases in a desert, can serve as valuable markers for monitoring the efficacy of temsirolimus.

Potential Benefits and Considerations for Patients with HNSCC

This research provides hope for patients with HNSCC, suggesting that temsirolimus may be an effective adjuvant therapy. It is important to note that the study evaluated the effects of temsirolimus in a specific setting, and further research is needed to determine its optimal use in clinical practice. As with any medical treatment, patients should discuss the potential risks and benefits of temsirolimus with their healthcare providers.

Dr.Camel's Conclusion

This study provides a valuable contribution to the understanding of temsirolimus’s potential as an adjuvant therapy for patients with HNSCC. It’s like finding a precious water source in a vast desert, offering new possibilities for treating this challenging disease. The research highlights the need for continued investigation to optimize the use of temsirolimus in clinical practice.

Date :
  1. Date Completed 2011-03-28
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

20222045

DOI: Digital Object Identifier

10.1002/hed.21374

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.